We have designed a drug delivery system for the anti-cancer drugs doxorubicin and mitoxantrone based on carbon nanotubes, which is stable under biological conditions, allows for sustained release, and promotes selectivity through an active targeting scheme. Carbon nanotubes are particularly promising for this area of application due to their high surface area, allowing for high drug loading, and their unique interaction with cellular membranes.
Introduction
Cancer is amongst the top three killers in modern society, next to heart and cerebrovascular diseases. In 2009, approximately eight million people died from cancer worldwide according to the WHO. The two chemotherapeutic drugs examined in this study, doxorubicin and mitoxantrone, are frequently used in the clinic for the treatment of a range of solid tumors, including breast and prostate cancers. However, both drugs are associated with severe, sometimes fatal cardiotoxicity due to a lack of target specificity [1] . Several attempts have been made to reduce this serious side effect, for example by liposomal encapsulation of doxorubicin (Myocet®) or liposomal encapsulation plus additional PEGylation (Doxil®).
Additionally, active drug targeting strategies are being developed to further enhance selectivity. In recent years, carbon nanotubes (CNTs) have emerged as promising candidates for a multimodal drug delivery system. They not only allow for the attachment of multiple copies of drug molecules, but can also be equipped with targeting agents and stealth molecules to evade clearance by the immune system. Furthermore, they hold several potential advantages over other nano-sized delivery systems, such as an exceptionally high drug loading capacity due to their high surface area and the possibility for incorporating additional therapeutic and diagnostic moieties, either on the surface or their inner cavity. In addition, they interact with cellular membranes in a unique way: some types of CNTs have been reported to enter mammalian cells by an endocytosis-independent, "needle-like" penetration mechanism, which allows for direct cytoplasmic delivery of therapeutic payloads [2, 3] . A number of studies have already reported successful delivery of anti-cancer drugs to human cancer cells or tumor xenografts by means of carbon nanotubes [4] [5] [6] [7] [8] [9] . Amongst these, doxorubicin has emerged as a favored drug candidate due to its inherent fluorescence, facilitating cellular imaging and quantitative assays based on absorption or fluorescence spectroscopy. However, no study to date has reported the delivery of mitoxantrone by carbon nanotubes, which is also a fluorescent anti-cancer drug with a similar mechanism of action to that of doxorubicin.
In this article, we focus on the fine-tuning of the functionalisation chemistry of carbon nanotubes for drug delivery applications, in particular with regard to therapeutic efficacy, biocompatibility and stability. We first investigated how the binding conditions during the drug loading step (e.g. pH, temperature, and light) influence the therapeutic activityof the drugs and, in the case of pH, their binding onto nanotubes, and took a systematic approach to PEG conjugation in order to achieve maximal dispersion stability. We then demonstrated pHdependent release of the drugs, which promoted their release inside cells upon internalisation.
We also studied drug release in cellular growth medium prior to cellular uptake, which is a possible mechanism for premature drug release. Cellular uptake and fate of the designed drug delivery vectors was visualised by confocal microscopy. Finally, the therapeutic efficacy of the drug-CNT complexes was evaluated by in vitro cell viability assays. The results indicate that interestingly, a stable dispersion is of minor importance for the therapeutic success of the system. Furthermore, the attachment of folate as a targeting agent significantly enhanced cytotoxicity, thereby achieving higher cell killing at lower drug concentrations combined with a certain selectivity for cancerous cells, as folate receptors are significantly upregulated by a broad spectrum of human cancers [10] .
Material and Methods

Material
The applied single-walled CNTs (SWCNTs) were produced by SouthWest 
Purification and acid oxidation
SWCNTs were first purified by incubation in concentrated nitric acid at 95 °C for 2 h. In a second step, the sample was oxidised by incubation in a 3:1 mixture of concentrated nitric and sulfuric acid at 95 °C for 2 h. Afterwards, the oxidised SWCNTs (oxSWCNTs) were washed by vacuum-assisted filtration using 0.2 µm polycarbonate filters (Whatman Ltd.)
until the eluate was clear and of neutral pH. Oxidation debris was removed by washing with sodium hydroxide (0.01 M) and three centrifugation steps at 75,000g were performed to remove big agglomerates and bundles. The concentration of the resulting dispersion was determined gravimetrically by filtering a known volume of oxSWCNT suspension using 0.2 µm polycarbonate filters (Whatman Ltd.), drying the filter for 1 h at 110 °C, and weighing the amount of oxSWCNTs on the filter paper using a microbalance. Finally, the concentration was adjusted to 200 µg/mL.
Sample characterisation
The obtained oxSWCNTs were then characterised by atomic force microscopy (AFM), UV/vis absorption spectroscopy and Raman spectroscopy. For AFM sample preparation, oxSWCNTs were diluted with water to obtain a concentration of 10 µg/mL and a droplet was placed onto a freshly cleaved mica substrate (1 cm 2 ) and dried in air. AFM measurements were performed using a PicoPlus instrument (Agilent Technologies, Chandler, AZ, USA) operated in contact mode at room temperature with a lateral scan rate of 1 -1.5 Hz at 512 lines. Data analysis was carried out using "Gwyddion 2.9", a free SPM data visualisation and imaging tool released under the GNU General Public License. UV/vis absorption spectroscopy was carried out using a Helios Alpha UV/Vis spectrophotometer from Thermo Scientific. Raman spectroscopy measurements were performed using a Renishaw microRaman instrument at an excitation wavelength of 785 nm. Acid-base titration to determine the number of total acidic sites was carried out as described in the supporting information. 
Optimisation
Effect of PEG density on drug loading
100 µg oxSWCNTs were PEGylated in the same way as described above, except that instead of various different PEG formulations, only branched PEG 2500-NH 2 was used (amounts added ranged from 5 µmol to 0.1 µmol). Considering that the amount of total acidic sites is about 0.15 µmol/100 µg oxSWCNTs (as determined in the supporting information), this corresponds to ratios of PEG molecules to acidic sites between 33.3 and 0.7. The measurement of drug binding and dispersion stability was also carried out in the same way as described above.
Drug release over time at different conditions
In order to measure drug release over time at different conditions, the two drugs doxorubicin and mitoxantrone were loaded onto oxSWCNTs functionalised with branched PEG 2500-NH 2 at a drug/CNT weight ratio of 1:2, which guarantees 100% drug binding. After incubation over night at 4 °C, the samples were mixed with 100 mM sodium phosphate buffer pH 5.5/7.4 or cellular growth medium (MEM, phenol red-free) and incubated at 37 °C for 24 h, 48 h, or 72 h. After each time point, 500 µL of each sample were filtered using 300 kDa Pall Nanosep® centrifugal devices and the amount of drug in the eluates analysed by UV/vis absorption spectroscopy (at 479 nm for doxorubicin or at 608 nm for mitoxantrone). false positive results in cytotoxicity assays [11] and cell viability evaluated by means of the MTT and WST assay. Each sample was tested in quadruplicate. Dose-response curves were generated by plotting cell viability against drug concentration. In order to obtain IC 50 values (i.e. the drug concentrations, at which 50% of the cell population is killed), curves were fitted using the four-parameter model, a widely-used model for fitting sigmoidal dose-response curves.
Functionalisation of PEGylated oxSWCNTs with folic acid and fluorescein
Confocal microscopy
Cultured cells in single cell suspension were seeded into 24-well tissue culture plates containing cover slips at a density of 75,000 cells per well. After an incubation period of 24 h under standard tissue culture conditions, the medium in the wells was replaced with a 1:1 mixture of the respective nanotube sample in cell medium and the plate incubated for 1 h, 3
h, or 5 h at 37 °C. Afterwards, the medium was aspirated off, the cells washed twice with PBS and incubated with 4% formaldehyde for 10 min. Next, ToPro3 nuclear stain in a 1:10,000 dilution (1 mL) was added to each well and the plate left to incubate for 10 min.
Finally, after abundant washing, the cover slips were mounted onto glass slides using VECTASHIELD® fluorescent mounting medium and sealed with nail polish. Confocal microscopy was carried out using a Zeiss LSM 510 confocal microscope in multichannel mode. Fluorescein-labeled structures were excited at 488 nm and emission detected at 500-550 nm, doxorubicin excited at 488 nm and detected at 650-710 nm, and TOPRO excited at 633 nm and detected at 650-710 nm.
Results and Discussion
Initially, the applied sample of oxidised, single-walled CNTs (oxSWCNTs) was characterised by various techniques and we investigated how the binding conditions during the drug loading step (e.g. pH, temperature, and light) influence the therapeutic activityof the drugs.
Next, binding of the drugs to oxSWCNTs was studied in respect to pH, and a systematic approach to PEG conjugation was undertaken in order to achieve maximal dispersion stability. After demonstrating pH-dependent drug release we visualized cellular uptake of drug-loaded oxSWCNTs PEG by confocal microscopy and finally compared their therapeutic efficacy to that of the free drugs and to drug-loaded oxSWCNTs PEG conjugated to the targeting agent folate.
Preparation and characterisation of the applied carbon nanotubes
In a previous study we compared five different types of oxidised CNTs with regard to their dispersion stability. Data suggested that oxSWCNTs produced by the CoMoCAT® method exhibited the highest dispersion stability, attributed to their short aspect ratio after acid oxidation [12] . We thus selected this nanotube sample as the most promising candidate for the development of a CNT-based drug delivery system. Raman spectroscopy, and UV/vis absorption spectroscopy. The mean particle size of the oxSWCNTs was about 126 ± 8 nm, as determined by phase analysis light scattering (PALS) [12] . Considering that pristine SWCNTs are between 450 and 2000 nm long (mode at 900 nm) according to the manufacturer, this demonstrates that the acid treatment has shortened the nanotubes by more than 90%, which is also evident in the AFM image ( Figure 1a ).
Further AFM analysis of this sample including higher magnification images can be found elsewhere [12] . Their Raman spectrum (Figure 1b ) featured three prominent peaks: the radial breathing mode (RBM) at 263 cm -1 , which is inversely proportional to the tube diameter, the disorder-related D-band at 1313 cm -1 , and the graphitic G-band at 1590 cm -1 . The intensity ratio of the D-to the G-band is an indicator of the structural disorder originating from the formation of in the graphitic structure. In the case of the oxSWCNTs examined in this study, the I D /I G ratio was 0.19 for pristine SWCNTs and 0.55 for oxidised SWCNTs, which indicated that the density of defects/functional groups was higher after oxidation. This also explains why the typical UV/vis features of non-oxidised SWCNTs were absent after acid oxidation ( Figure 1c ). It should furthermore be noted that the sample had been washed with NaOH and HCl after acid oxidation and was thus free of oxidation debris [13] .
3.2.
Fine-tuning of the functionalisation procedure
Degradation of doxorubicin and mitoxantrone as a function of pH, light, and temperature
The first experiment was designed to determine the optimal pH and temperature conditions for the two drugs. It is well-known that both doxorubicin and mitoxantrone are not ideal drugs from an analytical point of view. Doxorubicin is known to self-associate in concentrated solutions, is liable to photolytic decomposition and degrades at unfavorable pH conditions [14] . It is most stable at pH 4 and converts into the 7-hydroxyaglykone (detached amino sugar residue) in more acidic conditions and destabilises at basic pH due to enolisation of the C9 side chain. Similarly, mitoxantrone is also most stable at pH 4 and shows accelerated degradation at higher pH, under UV irradiation, and at higher temperatures [15] .
It furthermore forms precipitates upon refrigeration, which redissolve after warming to room temperature without a loss of efficacy [16] .
Drug delivery experiments are usually performed with a pH range of 5.5-7.5 to maintain cell viability, yet we and others [5] found that the binding of doxorubicin and mitoxantrone to
CNTs works best at high pH, at which the drugs are deprotonated. This indicates that very likely a compromise has to be found between achieving optimal drug loading, while maintaining the activity of the drugs. We therefore incubated both drug molecules at a range of pH (5-9) and temperatures (4 °C vs. 25 °C) for 3 days and then evaluated their cytotoxicity by means of MTT cell viability assays. pH. Doxorubicin incubated at 25 °C in daylight was unstable above pH 6 and rendered entirely inactive at pH 9. When the same solutions were incubated at 4 °C in the dark, however, doxorubicin did not lose its activity up to pH 8 but lost some activity at pH 9. This is in accordance with the literature [17] and shows that degradation of doxorubicin is considerably accelerated by light and high pH, possibly due to the promotion of oxidation reactions or the formation of drug polymers, which are incapable of penetrating the cellular membrane [18] . The self-aggregation of neutral antracycline molecules by π-stacking is consistent with our studies, which indicated that doxorubicin forms visible agglomerates above pH 7, with the extent of agglomeration correlating with a loss of activity (photograph beneath the diagram in Figure 2 ). In contrast, mitoxantrone was stable over the 3-day incubation period for all pH values (Figure 2b) , although some loss of activity was observed at pH 7 when incubated in daylight at 25 °C in light, but not at 4 °C in darkness.
Interestingly, the drug also tended to precipitate at pH 7 (and, to a lesser extent, at pH 6 or 8),
which correlated with the loss of activity at this pH. However, compared to doxorubicin this effect was much less marked, which is consistent with the fact that mitoxantrone solutions form precipitates when kept at low temperatures, whilst maintaining the cytotoxic effect [16] .
In conclusion, drug binding experiments should be performed at low temperatures and under protection from light to maintain drug activity and, for doxorubicin, at pH 8 or lower.
Effect of pH on drug binding
Next, we investigated the influence of the pH on drug binding. Both doxorubicin and mitoxantrone are able to attach to the surface of carbon nanotubes by π-π interactions due to their inherent aromatic structure. In addition, both drug molecules contain pH-sensitive amine groups, which makes their binding to nanotubes pH-dependent (enhanced at high pH and reduced at low pH [5] ). This potentially allows for drug release in acidic endosomes and the microenvironment of tumors. To evaluate the pH dependence of drug binding, oxSWCNTs were incubated with the two drugs at pH 5 to 9 for 18 hours, after which the samples were filtered and the quantity of unbound drug in the filtrate measured by UV/vis absorption spectroscopy. Samples without nanotubes (also from pH 5-9) served as controls. Figure 3 shows that, as expected, both doxorubicin and mitoxantrone bind to nanotubes to a greater extent with increasing pH, with maximal binding at pH 8-9. This is due to the majority of amino groups being deprotonated at these pH (having pKa values between 8.3 and 8.6 [19] ), making them more hydrophobic and capable of binding to the nanotube surface by π-π interactions. In combination with the results of the previous experiment, it can be concluded that a pH of 8 is optimal for the binding of doxorubicin to oxSWCNTs and a pH of 9 is optimal for mitoxantrone, provided that the binding reaction is carried out at 4 °C in the dark.
However, we noticed that the nanotubes precipitated out of solution during the drug-binding incubation. This was not surprising, as it is well-known that oxidised carbon nanotubes give rise to electrostatic interactions with salts, such as the two anticancer drugs investigated here, which can impair the dispersion stability due to charge neutralisation [20] . Precipitation did not influence the efficacy of drug binding; but it is of course essential that any clinical formulation remains stable in the circulation, so dispersion stability is critical. In a previous study we have shown that the dispersion stability of oxidised nanotubes and also their biocompatibility toward cancer cells can be improved by covalent conjugation to polyethylene glycol (PEG) [12] . PEGylation is also a widely-used pharmaceutical formulation strategy in clinical settings, as it reduces immunogenicity and non-specific interactions with plasma proteins, while concomitantly prolonging blood circulation times.
We, therefore, attempted to optimise dispersion stability of PEGylated oxSWCNTs in the presence of the drugs while monitoring the degree of drug loading. [21] and Marega et al. [22] . As a fifth candidate, we investigated an amine-terminated phospholipid-PEG (PL-PEG2000-NH 2 ), which is widely used as a dispersion agent for carbon nanotubes [23, 24] . In this case the functionalisation was based on non-covalent interactions promoted by the binding of the phospholipid-moiety to the nanotube surface. The ideal PEG candidate should optimally stabilise nanotube dispersions without impairing drug binding through steric hindrance or repulsive electrostatic interactions.
Effect of the type of PEG on drug loading and dispersion stability
Figure 4
Effect of the PEG type on drug binding and dispersion stability: Only one PEG candidate -branched PEG 2500-NH 2 -was able to promote a stable dispersion after addition of the drugs, whereas in all other cases, the nanotubes precipitated out of solution. 
Effect of the degree of PEGylation on drug loading
The optimal PEG molecule (branched PEG 2500-NH 2 ) was conjugated to oxSWCNTs at various concentrations to investigate the effect of PEG density on drug loading and dispersion stability. In this experiment, the nanotube concentration was kept constant, while branched PEG was added at amounts ranging from 5 µmol to 0.1 µmol. After the conjugation reaction, unreacted PEG molecules were removed by filtration through 0.2 µm polycarbonate filters and repeated washing. As illustrated in Figure 5a , the more PEG was added initially, the lower was the drug binding. Although we did not determine the actual amounts of PEG attached to the oxSWCNTs after the coupling reaction, we presume that adding a higher amount of PEG during the reaction leads to a higher PEG density of the final product, which may impair drug binding due to sterical hindrance. Dispersion stability, on the other hand, significantly improved with increasing initial amounts of PEG used ( Figure 5b) ; in fact only the highest amount of PEG added (5 µmol or a 33-fold molar excess) was able to maintain a sufficiently stable dispersion after addition of the drugs. When comparing the two drugs, mitoxantroneloaded oxSWCNTs PEG (mito-oxSWCNTs PEG ) were less stable than doxorubicin-loaded oxSWCNTs PEG (dox-oxSWCNTs PEG ); presumably because mitoxantrone is a bivalent salt, whereas doxorubicin is monovalent. For subsequent experiments, branched PEG 2500-NH 2 was used at an initial amount of 5 µmol to ensure maximal dispersion stability, although this compromised drug binding by about 40%. Furthermore, we used a drug/oxSWCNT PEG weight ratio of approximately 1:2 in order to obtain quantitative drug binding and thus eliminating the need for a filtration step to remove unbound drug, which corresponded to a final drug concentration of 25 µM (or 14.5 µg/mL doxorubicin and 12.9 µg/mL mitoxantrone, respectively) and a final oxSWCNT PEG concentration of 25 µg/mL. The absence of free drug (at zero time) is demonstrated in the next section.
Drug release over time at different conditions
The release of both doxorubicin and mitoxantrone should be promoted at low pH due to their amine functionalities, which render them hydrophilic at low pH and hydrophobic at high pH.
To confirm this effect at pH 5.5, which is the approximate pH the drug delivery sytem would encounter in the endosomal pathway, we incubated dox-oxSWCNTs PEG or mitooxSWCNTs PEG in buffers at pH 7.4 or 5.5 for 3 days. After every 24 h, the samples were filtered and the released drug in the eluates was measured by UV/vis absorption spectroscopy. Drug release was also assayed in cell culture growth medium (buffered at pH 7.4), mimicking the conditions of a typical cell viability assay. As observed in Figure 6 , the drugs were gradually released from their nanotube carrier at pH 5.5 with 44% of doxorubicin and 55% of mitoxantrone released after 72 h. In contrast, only 7% of doxorubicin and 8% of mitoxantrone was released at pH 7.4 after the same time.
Incubation of the drug-oxSWCNT PEG conjugates in cell growth medium did however release significant quantities of drug: 23% of doxorubicin and 21% of mitoxantrone by 72 h. This suggests that bound drugs were gradually being displaced on the nanotube surface by components of the cell culture medium during the incubation, most probably by serum proteins from the fetal calf serum component. This potentially allows for extracellular release of the drug from the nanotube carrier and its subsequent diffusion through the cell membrane without its nanocarrier, although this would only occur for long blood circulation times (1-3 days).
Intracellular distribution of CNT PEG -doxorubicin conjugates
Hela cells were incubated with dox-oxSWCNTs PEG for 4 h (Figure 7 ) and drug uptake monitored by confocal microscopy, taking advantage of the inherent fluoresence of doxorubicin. The confocal images show that doxorubicin (red, Figure 7b ) was entirely located in the cell nucleus (counterstained with ToPro 3, in blue, Figure 7c ), proving its release from the nanotubes (labelled with fluorescein, in green), which were distributed as discrete spots in the cytoplasm (Figure 7a ), indicating localisation within endosomes. This suggests an endocytotic, energy-dependent uptake mechanism, which would lead to the engulfment of the drug-SWCNT-complexes in endosomes and subsequent release of the drug due to the lower endo-/lysosomal pH (as also shown in Figure 6) . The drug would then translocate to the cell nucleus to exert its cytotoxic action; interference with DNA replication [26] . The exact uptake mechanism and fate of CNTs inside cells is currently further investigated in our laboratory and will be published separately [27, 28] . It is important to note that a small amount of doxorubicin has been found to detach from its CNT carrier extracellularly during incubation in cellular growth medium ( Figure 6 ) and can potentially diffuse through the cell membrane on its own.
Effect of dispersion stability on uptake and activity of the drug-SWCNT complexes
We first aimed to investigate whether the dispersion stability of drug-loaded oxSWCNTs affects the drugs' therapeutic activity on cultured cells. Two types of oxSWCNTs were used, oxSWCNTs reacted with 5 mM PEG and "naked" oxSWCNTs, associated with dispersion stabilities of 90-100% and 0%, respectively. In order to evaluate cytotoxicity, we used both the MTT and the WST assay and compared the results of the two, as the former is known to cause false positive test results due to interactions of the hydrophobic end product MTTformazan with the CNT surface, which can occur outside as well as inside cells [11] . The WST assay follows the same assay principle as the MTT assay, but its end product is hydrophilic and therefore not prone to attach to the surface of CNTs (please see the supporting information for a full comparison between the two assays and the impact on this experiment This is likely due to drug molecules taken up by passive transport being free to translocate directly to the nucleus, where they exert cytotoxicity, whereas drug molecules complexed to carbon nantubes are released only after encountering the lower pH inside endosomes and lysosomes and so lower amounts reach the nucleus to excert a cytotoxic effect. The next step was to investigate, whether the attachment of a targeting agent could improve the complexes' cytotoxicity and additionally provide specificity to cancerous cells. We chose folic acid as a targeting agent, as the folate-receptor is significantly upregulated by a broad spectrum of human cancers, in some cases by two orders of magnitude, facilitating cellular internalisation of folate-conjugated nanocarriers by receptor-mediated endocytosis [10, 29] . Additionally, non-cancerous cells only transport folate by this receptor but not folate conjugates of any type [30] , which adds an extra level of specificity. Folic acid was covalently attached folate to the amine termini of the PEG chains, as described in the methodology, and Hela cells maintained in folate-depleted growth medium for several passages to induce overexpression of the folatereceptor. Subsequently, the cells were incubated with the folate-targeted drug-oxSWCNT PEG complexes for 96 h as described above and cytotoxicity evaluated by means of the WST assay. confirming the selectivity of the targeting approach and its advantage over using the free drug.
Conclusions
We have developed a carbon nanotube-mediated drug delivery system for two different anticancer drugs, affording high biological and chemical stability, high drug loading and selective cancer treatment in an in vitro scenario by an active targeting scheme. After finetuning the synthesis parameters to obtain maximal drug loading, while maintaining the dispersion stability of the system, we demonstrated pH-dependent drug release in buffer solutions and confirmed cellular uptake of the nanovectors and intracellular drug release, by means of confocal microscopy. Finally, we evaluated the therapeutic efficacy of the system in cell viability assays and found that while drug-loaded nanotubes were less effective than the free drugs, attachment of the targeting agent folic acid significantly enhanced the efficacy and selectivity of the system. Keeping in mind that free doxorubicin and mitoxantrone are both highly effective in in vitro experiments due to their aqueous solubility and membrane permeability, this is an encouraging result. The targeted, drug loaded nanotubes are selective in contrast to the free drugs and additionally allow for sustained release, which is likely to reduce drug-related side effects in animal models and clinical studies. Overall, our study demonstrates the potential of carbon nanotubes as a multimodal drug delivery system and presents a functionalisation scheme that is able to overcome many of the problems encountered in this area of application. Figures   Figure 9 Characterisation of the used oxSWCNTs by a) atomic force microscopy, b) Raman spectroscopy, and c) UV/vis absorption spectroscopy. candidate -branched PEG 2500-NH 2 -was able to promote a stable dispersion after addition of the drugs, whereas in all other cases, the nanotubes precipitated out of solution. 
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